STADA

Investor News

Investor News

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

Bad Vilbel, February 1, 2018 – The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018. Peter Goldschmidt will take over from Dr. Claudio Albrecht who has been the CEO at STADA since September 27, 2017. Since 2013, Peter Goldschmidt serves as the President and Head of North America at Sandoz Inc., responsible for the Company’s North American operations.

Mark Keatley, Chief Financial Officer, and Dr. Barthold Piening, Chief Technical Officer, will keep their positions on the STADA Executive Board.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-Mail: leslie.iltgen(at)stada.de

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Learn more

Sustainability

Sustainability

For STADA "All the best" means taking responsibility.

Learn more

entdecken